NCT02971631View on ClinicalTrials.gov

Gastrectomy, Eating Behaviour and GLP-1

NACompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

August 10, 2017

Primary Completion Date

September 16, 2018

Study Completion Date

September 16, 2018

Conditions
Gastric CancerDumping Syndrome
Interventions
OTHER

Exendin 9-39

Complete blockade of action of endogenous GLP-1 by Exendin 9-39. Defined as a physiological study, not a clinical trial as such (as advised by the UK MHRA).

OTHER

Placebo

Infusion of 1% human albumin in normal saline

Trial Locations (1)

CB2 0QQ

Cambridge University Hospitals NHS Foundation Trust, Cambridge

All Listed Sponsors
lead

Cambridge University Hospitals NHS Foundation Trust

OTHER

NCT02971631 - Gastrectomy, Eating Behaviour and GLP-1 | Biotech Hunter | Biotech Hunter